Wayfinder Medical
Wayfinder Medical
Navigate what comes next
CONDITION GUIDE

Friedreich Ataxia

Friedreich Ataxia

Medical Overview

Friedreich ataxia (FA) is a progressive genetic disorder that damages the nervous system and the heart. It is caused by a mutation in the FXN gene on chromosome 9, which produces a protein called frataxin. Without enough frataxin, iron accumulates in the mitochondria of cells, causing oxidative damage to nerves, the heart, and the pancreas.

FA is an autosomal recessive condition -- you need two copies of the mutated gene (one from each parent) to develop it. In about 96% of cases, the mutation is a GAA trinucleotide repeat expansion in the FXN gene. Longer repeat lengths generally correlate with earlier onset and more severe disease.

Symptoms usually begin between ages 5 and 15, though onset can range from age 2 to after 25. The first symptom is typically difficulty walking -- unsteadiness, frequent stumbling, and a progressive loss of coordination. The condition gets worse over time.

Core features include: Most people with FA need a wheelchair within 10-15 years of symptom onset. Cardiomyopathy is the leading cause of death, and life expectancy is reduced, typically to the 40s or 50s, though this varies.

FA is the most common inherited ataxia, affecting approximately 1 in 50,000 people. It is most common in people of European descent. An estimated 1 in 100 people of European ancestry are carriers of the gene mutation.

Diagnosis & Treatment

Getting Diagnosed

Diagnosis begins with recognizing the pattern: a young person with progressive difficulty walking, loss of reflexes in the legs, and scoliosis. A neurological examination reveals ataxia, absent deep tendon reflexes (unlike most other ataxias where reflexes may be increased), and sensory loss.

Genetic testing confirms the diagnosis by identifying the GAA repeat expansion in the FXN gene. This is now the definitive diagnostic test. Supporting tests: Diagnosis can be delayed if doctors are not familiar with FA or if the pattern is mistaken for other conditions. The combination of ataxia with absent reflexes (rather than increased reflexes) and early-onset scoliosis should raise suspicion.

Treatment

There is no cure. Treatment focuses on managing symptoms, slowing progression where possible, and addressing cardiac and metabolic complications.

In 2023, omaveloxolone (Skyclarys) became the first FDA-approved treatment for Friedreich ataxia. It works by activating a pathway (Nrf2) that reduces oxidative stress. Clinical trials showed it slowed the progression of neurological symptoms. It does not reverse existing damage. Other treatments: Ongoing research includes gene therapy approaches to increase frataxin production, antisense oligonucleotides, and other compounds targeting mitochondrial function and iron metabolism. Multiple clinical trials are active.

Accommodation Strategies

FA is a progressive condition that affects mobility, coordination, speech, and stamina. Accommodations need to evolve as the condition advances.

Early stage (ambulatory): Middle stage (using mobility aids): Advanced stage (wheelchair-dependent): The Job Accommodation Network (JAN) provides specific guidance for progressive neurological conditions. Under the ADA, accommodations must be updated as functional capacity changes.

Benefits & Disability

Friedreich ataxia is a progressive condition that will eventually qualify most people for disability benefits.

Social Security Disability (SSDI/SSI)

The SSA evaluates FA under:

The progressive nature of FA means that even if you do not meet the listing criteria at the time of initial application, you likely will as the condition advances. Early documentation of decline is critical. Key documentation: Neurological exam findings showing progressive ataxia, loss of reflexes, and sensory deficits. Cardiac evaluations documenting cardiomyopathy. Genetic test results confirming the diagnosis. Functional assessments showing what you can and cannot do -- walking distance, stair use, fine motor tasks, speech intelligibility.

Long-Term Disability Insurance

If you have employer-provided LTD coverage, file a claim when FA prevents you from performing your job duties. The progressive and well-documented nature of FA generally supports these claims, but you need ongoing medical documentation.

Notable Public Figures

Friedreich ataxia has gained visibility through several patient advocates and public figures.

Kyle Bryant, founder of the Friedreich's Ataxia Research Alliance (FARA) ride program, has been one of the most visible advocates, using cycling events to raise awareness and research funding.

The Friedreich's Ataxia Research Alliance and the National Ataxia Foundation have cultivated a community of patient advocates who share their stories publicly, particularly through social media and fundraising events. These advocates have been instrumental in driving research funding and the approval of omaveloxolone.

The condition remains relatively unknown to the general public, but within the rare disease community, FA advocacy is well-organized and effective.

Newly Diagnosed

If you or your child has just been diagnosed with Friedreich ataxia, here is what you need to know.

The diagnosis is confirmed by a genetic test. If you have not had genetic confirmation, get it. The GAA repeat expansion in the FXN gene is definitive. This is progressive, and that is a hard truth. FA gets worse over time. The rate of progression varies -- some people maintain walking ability for many years, while others need a wheelchair within a decade of onset. But knowing the trajectory allows you to plan. Cardiac monitoring is not optional. Cardiomyopathy is the leading cause of death in FA. Regular echocardiograms and cardiac care are essential, even when heart symptoms are not yet apparent. Start physical therapy immediately and keep it going. Maintaining strength, flexibility, and function for as long as possible is the single best thing you can do. Do not wait until mobility is significantly impaired. Omaveloxolone (Skyclarys) is now available. Talk to your neurologist about whether it is appropriate. It is the first FDA-approved treatment and has been shown to slow progression, though it does not reverse existing damage. Genetic counseling matters. FA is autosomal recessive. If you are a parent of a child with FA, both of you carry the gene. Siblings have a 25% chance of being affected. This information matters for family planning. Connect with the community. The Friedreich's Ataxia Research Alliance (curefa.org) and the National Ataxia Foundation (ataxia.org) provide research updates, support networks, and patient advocacy resources. You are not navigating this alone.

Culture & Media

Friedreich ataxia has limited but growing representation in media. The condition has been featured in rare disease awareness campaigns and documentary-style content produced by advocacy organizations.

Patient-created content on YouTube, Instagram, and TikTok has been a significant driver of awareness, particularly among younger audiences. People living with FA share their daily lives, therapy routines, adaptive strategies, and the emotional reality of progressive disability.

The approval of omaveloxolone in 2023 generated media coverage that brought FA into broader public awareness for the first time, framed as a breakthrough in rare disease treatment.

Within the disability community, FA advocates have contributed to broader conversations about progressive disability, accessibility, and the gap between what accommodation law promises and what workplaces actually provide.

Creators & Resources

Organizations

Support Communities

Medical Resources

Key Statistics